[HTML][HTML] Update on fibroblast growth factor 23 in chronic kidney disease

M Wolf - Kidney international, 2012‏ - Elsevier
Chronic kidney disease (CKD) is a public health epidemic that affects millions of people
worldwide. Presence of CKD predisposes individuals to high risks of end-stage renal …

The chronic kidney disease—Mineral bone disorder (CKD-MBD): Advances in pathophysiology

KA Hruska, T Sugatani, O Agapova, Y Fang - Bone, 2017‏ - Elsevier
The causes of excess cardiovascular mortality associated with chronic kidney disease
(CKD) have been attributed in part to the CKD-mineral bone disorder syndrome (CKD-MBD) …

[HTML][HTML] Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production

V David, A Martin, T Isakova, C Spaulding, L Qi… - Kidney international, 2016‏ - Elsevier
Circulating levels of fibroblast growth factor 23 (FGF23) are elevated in patients with chronic
kidney disease (CKD), but the mechanisms are poorly understood. Here we tested whether …

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

T Isakova, H **e, W Yang, D **e, AH Anderson… - Jama, 2011‏ - jamanetwork.com
Context A high level of the phosphate-regulating hormone fibroblast growth factor 23 (FGF-
23) is associated with mortality in patients with end-stage renal disease, but little is known …

[HTML][HTML] Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy

MC Hu, M Shi, N Gillings, B Flores, M Takahashi… - Kidney international, 2017‏ - Elsevier
α-Klotho is highly expressed in the kidney, and its extracellular domain is cleaved and
released into the circulation. Chronic kidney disease (CKD) is a state of α-Klotho deficiency …

[PDF][PDF] Clinical practice guideline for the management of chronic kidney disease‐mineral and bone disorder

M Fukagawa, K Yokoyama, F Koiwa… - … Apheresis and Dialysis, 2013‏ - jsdt.or.jp
Masafumi Fukagawa, 1 Keitaro Yokoyama, 1 Fumihiko Koiwa, 1 Masatomo Taniguchi, 1
Tetsuo Shoji, 1 Junichiro James Kazama, 1 Hirotaka Komaba, 1 Ryoichi Ando, 1 Takatoshi …

Role of chronic kidney disease (CKD)–mineral and bone disorder (MBD) in the pathogenesis of cardiovascular disease in CKD

S Yamada, T Nakano - Journal of atherosclerosis and thrombosis, 2023‏ - jstage.jst.go.jp
Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney
disease (CKD). Multiple factors account for the increased incidence of cardiovascular …

Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)

JH Ix, R Katz, BR Kestenbaum, IH de Boer… - Journal of the American …, 2012‏ - jacc.org
Objectives: This study sought to determine the association of fibroblast growth factor (FGF)-
23 with death, heart failure (HF), and cardiovascular disease (CVD) in the general …

Chronic kidney disease–mineral and bone disorder (CKD-MBD): current perspectives

B Waziri, R Duarte, S Naicker - International journal of nephrology …, 2019‏ - Taylor & Francis
Despite the availability of global and regional guidelines to curtail the adverse clinical
outcomes associated with chronic kidney disease–mineral and bone disorder (CKD-MBD) …

Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

M Leifheit-Nestler, R große Siemer… - Nephrology Dialysis …, 2016‏ - academic.oup.com
Background In chronic kidney disease (CKD), serum concentrations of fibroblast growth
factor 23 (FGF23) increase progressively as glomerular filtration rate declines, while renal …